<DOC>
	<DOCNO>NCT02564614</DOCNO>
	<brief_summary>This open-label study demonstrate proof-of-mechanism HIF1A inhibition decrease HIF1A mRNA intravenous ( IV ) infusion RO7070179 participant hepatocellular carcinoma ( HCC ) fail least one line systemic therapy . This single arm study participant receive RO7070179 , 13 milligram per kilogram per week ( mg/kg/week ) , 2-hour IV infusion Days 1 4 Week 1 Cycle 1 , follow weekly 6 week cycle . Treatment RO7070179 continue disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Study Hypoxia-inducible Factor 1a ( HIF1A ) Messenger Ribonucleic Acid ( mRNA ) Antagonist ( RO7070179 ) , Demonstrate Proof-of-mechanism Adult Participants With Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Male female &gt; =18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status 01 , ChildPugh score 57 , Life expectancy 3 month great . Confirmed HCC describe American Association Study Liver Disease ( AASLD ) . Participants fail least one line systemic therapy advance stage HCC participant ineligible unable tolerate standard care treatment . Have measurable evaluable disease . Participants normal major organ function define hemoglobin ( HgB ) &gt; = 8.5 gram/decilitre ( dL ) , absolute neutrophil count ( ANC ) &gt; = 1000/microliter ( mcL ) , platelet &gt; = 60,000/micL , aspartate aminotransferase/alanine transaminase ( AST/ALT ) &lt; = 3 x Upper Limit Normal ( ULN ) , total Bilirubin &lt; = 2 x ULN , creatinine &lt; = 2 x ULN . Willingness undergo two tumor biopsy : administration RO7070179 . Concurrent serious medical illness could potentially interfere protocol compliance ( medical illness include hepatitis cirrhosis , degree liver impairment cause disease cover exclusion criterion ) . Active hepatitis B C , participant stable medication hepatitis B C. Bleeding esophageal gastric varix within 2 month enrollment . Participants need take therapeutic anticoagulation antiplatelet therapy . Presence ascites preclude biopsy liver lesion . History unstable angina myocardial infarction within 12 month prior Day 1 ischemic heart disease . Known HIV positive positive screening pregnancy test breastfeeding . Female male reproductive capacity unwilling use method contraception prevent pregnancy study . Participants unwilling use method contraception prevent pregnancy 6 month last dose RO7070179 due potential prolong halflife RO7070179 liver . Known , clinically suspect , history CNS tumor involvement . Prior chemotherapy , immunotherapy , investigational therapeutic agent , therapy use treat HCC within 4 week first schedule administration RO7070179 . Participants recover reversible side effect ( except alopecia ) Grade 0 1 toxicity attribute administration investigational therapeutic agent , chemotherapy , immunotherapy , radiotherapy , agent previously use treat cancer . Any condition , opinion investigator Sponsor , make patient unsuitable study . Inability comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>